Background Mutations in the genes called BRCA1 and BRCA2 are associated with
significantly elevated lifetime risk of developing breast and ovarian cancer. This year marks …

Since the cloning of BRCA1 and BRCA2, genetic testing for breast and ovarian cancer
susceptibility has become more widespread. However, interpretation of test results is not …

Testing for mutations in breast cancer genes 1 and 2 (BRCA1/2) has been available since
1998, but much of the focus of this testing has been on the implications for women (Weitzel …

Since the 1990 s discovery of BRCA1 and BRCA2 pathogenic variants in breast or ovarian
cancer patients, genetic testing has been recommended as part of a targeted, individualized …

Genetic testing for mutations in BRCA1 and BRCA2, which are associated with increased
lifetime risk of breast and ovarian cancer, may become the first widely accessible genetic …

Germline BRCA1/2 testing of breast and ovarian cancer patients is growing rapidly as the
result affects both treatment and cancer prevention in patients and relatives. Through the …

Hereditary breast and ovarian cancer syndrome is an autosomal dominant cancer
susceptibility syndrome mainly due to variants in BRCA1 or BRCA2 genes. Patients …

Purpose: Women carrying BRCA1/BRCA2 germ-line mutations have an increased risk of
developing breast/ovarian cancer. To minimize this risk, international guidelines recommend …

Background The risks of breast cancer associated with BRCA1 and BRCA2 mutations vary
considerably across studies but few have assessed prospective risks, which are likely to …

Background Women from families with a high risk of breast or ovarian cancer in which
genetic testing for mutations in the BRCA1/2 genes is inconclusive are a vulnerable and …